Abstract Background The Ghent Older People's Prescriptions community Pharmacy Screening (GheOP 3 S-)tool was recently developed to screen for potentially inappropriate prescribing (PIP). Objective We aimed (1) to determine PIP prevalence in older nursing home (NH) residents with polypharmacy using the GheOP 3 S-tool and (2) to identify those PIPs that are most frequently detected. Method A cross-sectional study was carried out between February and June 2014 in 10 NHs in Belgium, supplied by a community pharmacy chain. For each NH, 40 residents (C70 years, using C5 chronic drugs) were included. PIP prevalence was determined using the GheOP 3 S-tool. Results 400 NH residents were included [mean age (±SD) 86.2 (±6.3) years; median number of drugs (±IQR) 10 (7-12)]. A total of 1728 PIPs were detected in 387 (97 %) participants (Median 4; IQR 2-6). The most prevalent items can be assigned to three categories: long-term use of central nervous system drugs (i.e. benzodiazepines, antidepressants and antipsychotics), use of anticholinergic drugs (mutual combinations and with underlying constipation/dementia) and underuse of osteoporosis prophylaxis. Conclusion Screening for PIP by means of the GheOP 3 S-tool revealed a high prevalence of PIP among older NH residents with polypharmacy. This finding urges for initiatives on the patient-level, but also on a broader, institutional level.
Introduction
Nursing home residents are particularly vulnerable to (potentially) inappropriate prescribing ((P)IP) as they are more fragile, receive therapy from multiple health care workers and are often prescribed a high number of drugs [1] . It makes prescribing in this setting a complex and challenging task [2, 3] . Additionally, PIP (i.e. overuse, underuse and misuse of drugs) is often associated with increased prevalence of adverse drug events (ADEs) and Electronic supplementary material The online version of this article (doi:10.1007/s11096-016-0366-6) contains supplementary material, which is available to authorized users. health care utilization [4] . Other health care professionals such as pharmacists and nurses, could assist physicians in the medication management process to ensure the most effective and safe pharmacotherapy for the patient [5] .
Screening of medication by pharmacists, preferably as a part of a full medication review with multidisciplinary consultation, is a proposed strategy to improve the appropriateness of prescribing [1, 6, 7] and has been shown to be effective [5] . However, significant improvements on hospitalizations or mortality are currently lacking [7] . This is probably due to the use of inappropriate outcome measures (i.e. number of drugs, MMSE-improvement etc.), a lack of power to detect statistically significant differences ormost importantly-the poor acceptance rate and continuation of recommendations resulting from the reviews [5, 8] . Additionally, there exist practical barriers to the systematic performance of a medication review among nursing home residents. This includes the lack of pharmacists with specific training in geriatric pharmacotherapy, the lack of centralized medical records and insufficient computerized support [8] .
Recently, we developed the Ghent Older People's Prescriptions community Pharmacy Screening (GheOP 3 S-) tool, an explicit screening tool to detect PIPs with high clinical relevance for older patients [9] . This screening tool provides the community pharmacist with the possibility to initiate a medication review process in a systematic and straightforward way, solely based on medication dispensing data available in the community pharmacy. Ideally, the results of a medication screening with the GheOP 3 S-tool should be discussed with the prescribing physician to confirm clinical relevance for the specific patient. Based on the outcomes of the pharmacistphysician consultation, suggestions for medication changes are proposed. Lastly, these suggestions are to be discussed with the patient, and a final treatment plan is to be decided on. The GheOP 3 S-tool has already been tested in ambulatory patients [10] , where it showed to detect all three categories of PIP: overuse, misuse and underuse.
Aim of the study
In the current observational study, we aim to perform a screening for PIP in nursing home residents using the GheOP 3 S-tool and to identify those PIPs that are most frequently detected.
Ethics approval
Ethics approval was received from the Ethics Committee of the Ghent University Hospital.
Method
This manuscript describes a cross-sectional study, carried out between February and June 2014, in 10 nursing homes in Flanders (i.e. the Dutch speaking part of Belgium) supplied by a community pharmacy chain. The pharmacy chain provided the research centre with an anonymized dataset, previously set up to examine problems for robotic unit dose drug dispensing. This database was set up as follows: 10 nursing homes were randomly selected out of a sample of 33 nursing homes which are all supplied by the community pharmacy chain. From each selected nursing home, forty residents meeting the following inclusion criteria were randomly selected: (1) aged 70 years or older and (2) using 5 of more chronic (i.e. according to a set regimen) drugs registered in the Belgian Commented Drugs Repertory [11] . The dataset contained the residents' medication records and basic demographics (age and gender). Each drug was assigned a seven-digit code in accordance with the Anatomical Therapeutic Chemical (ATC) Classification System formulated by the World Health Organization Collaborating Centre for Drug Statistics Methodology [12] .
We applied the GheOP 3 S-tool [9] to the patients' chronic medication in the received dataset. The choice to use this screening-tool was deliberate. First, the GheOP 3 Stool makes it possible to screen for PIP in settings where clinical data are not available. Second, the GheOP 3 S-tool is adapted to the European market and addresses all types of PIP. Third, the GheOP 3 S-tool offers the pharmacists a backbone to get started with the process of a medication review. An elaborate document describing rationale, alternative treatment plans and scientific background information empowers the pharmacists to initiate pharmacist-physician contacts to discuss the considered clinically relevant PIP-items. The GheOP 3 S-tool consists of 83 items, categorized in 5 different parts (Part 1: Potentially inappropriate drugs, independent of diagnosis, Part 2: Potentially inappropriate drugs, dependent on diagnosis, Part 3: Potential Prescribing Omissions (PPOs), Part 4: Drug Drug Interactions (DDIs) of specific relevance and Part 5: General care-related items to be addressed in the community pharmacy). Part 5 of the GheOP 3 S-tool was not applied in the current study as this part reflects on pharmacy work processes and is not applicable to the bulk supplying for nursing homes. With regard to the diagnoses in Part 2, drug proxies were used. Only diagnoses that unambiguously could be derived from the patient's medication (e.g. diabetes from insulin, gout from allopurinol, etc.) were taken into account. We also identified the GheOP 3 S-criteria that accounted for the highest proportion of PIP. The PIP screening with the GheOP 3 S-tool was performed manually by 3 researchers (EP, CVD and KM) and double-checked by the main investigator (ET). The STROBE standardized reporting guidelines for cross-sectional studies were followed to ensure the uniform conduct and reporting of the research [13] . Descriptives were displayed as counts with percentages and means with standard deviations or medians with interquartile ranges as appropriate. The PIP prevalence is represented as the proportion of residents with at least one PIP and the median number of PIPs per resident.
Results
The 400 randomly included residents had a mean age (±SD) of 86.2 (±6.3) years with 63 % of residents (250) Table 1 . The items of Part 2
and Part 3 are displayed in two ways; relative to the total population and relative to the overall drug or disease prevalence. A complete list of the prevalence of all individual GheOP 3 S-criteria is reported as Online Supplement.
Discussion
In this observational study, we detected at least one PIP in 97 % of the 400 randomly included nursing home residents, with a median of 4 PIPs per resident. This is in concordance with two other Belgian studies and with studies from other European countries [3, 5, 14, 15] . Some studies report lower prevalence rates, however in these cases, the researchers evaluated PIP with a smaller subset of published criteria or only screened for one aspect of PIP (e.g. underuse) [16, 17] . On the other hand, compared with a recent systematic review, estimating PIP prevalence in the ambulatory setting [18] , the prevalence in nursing homes is markedly higher. Although, one previously performed study with the GheOP 3 S-tool in the ambulatory setting observed a comparable PIP prevalence (at least one PIP in 97 % of patients, median of 3 PIP per patient) [10] .
The fact that nearly all patients had at least one PIP shows that there is a large room for improvement on the appropriateness of prescribing. During the development of the GheOP 3 S-tool, the experts unanimously agreed on the clinical relevance of screening for all included items in older patients in general. Whether the detected problems are also clinically relevant for the individual patient, still needs to be assessed during a pharmacist-physician consultation and agreement. The actual rate of inappropriate prescribing will therefore probably be somewhat lower.
The most prevalent PIP-items identified by the GheOP 3 s-tool can be assigned to the following three main categories: long-term use of drugs that influence the central nervous system (i.e. hypnosedatives, antidepressants and antipsychotics), use of anticholinergic drugs (mutual combinations and with underlying constipation or dementia) and underuse of osteoporosis prophylaxis. Additionally, the use of systemic NSAIDs and the long-term use of high-dose PPIs is frequent in this population. All of these items are also mentioned by other European observational studies [2, 8, 19] . In the observational study, using the GheOP 3 S-tool in the ambulatory setting, the same items (except for the use of anticholinergic drugs) significantly added to the number of PIP [10] . As the use of drugs that RAAS renin angiontensin aldosteron system influence the central nervous system and drugs with anticholinergic effects significantly adds to the high number of PIP, with possible significant clinical consequences as a result, the inappropriate use of these drug classes should be targeted first. Multiple trials already addressed these specific issues and showed that deprescribing in nursing homes is possible, improves the quality of prescribing and has a positive effect on the quality of life of the patient. One example is the study be Bourgeois et al. [20] , in which 66 % of chronic benzodiazepine users were successfully discontinued after 8 months, with an improved self-perceived sleep quality and significantly less midnight awakenings [20] . Another example, a randomized controlled trial performed in 22 nursing homes, showed that the anticholinergic burden was significantly reduced by a pharmacist-initiated medication review [21] .
Despite the fact that the GheOP 3 S-tool was developed to detect PIP on the patient level, this study also shows that an overall analysis, applied to all residents of one institution, could expose the most urgent issues on a more general level. This way, the GheOP 3 S-tool might serve as a benchmarking instrument for the prescribing behaviour in a nursing home. The result of such an overall analysis would be the ideal starting point for interdisciplinary case-conferences or the basis for targeted action plans. Using the GheOP 3 S-tool, the dispensing pharmacist is able to assist prescribers and the nursing home management to increase the quality of prescribing.
Strengths and limitations
This study shows that the recently developed GheOP 3 Stool, a validated community pharmacy specific list where limited clinical data are available, is practical and straightforward in screening for PIPs in nursing home residents. This study has nevertheless some limitations. As the GheOP 3 S-tool is explicit of nature, it does not take into account all patient factors in evaluating the pharmacotherapy, e.g. diagnoses, patient preferences or earlier attempts to tackle PIP. Also, some relevant items might have been missed. To tackle this, a future study will compare a GheOP 3 s-screening with a full medication review. This way, the items that are systematically missed will be identified and added to the GheOP 3 S-tool in a future update. Additionally, there were no pharmacistprescriber contacts to discuss the clinical relevance of the detected items. E.g. the clinical relevance of the interaction between a selective b-blocker and oral antidiabetics/insulin is minimal if glycemic control is good. Also, it is difficult to estimate generalizability to other countries as prescribing behavior can largely differ between geographical regions. Despite the fact that our results match findings from other European countries, it would still be interesting to compare our results to a GheOP 3 S-tool application in other European countries.
Conclusion
Screening for PIP by means of the GheOP 3 S-tool showed a high PIP prevalence in older nursing home residents with polypharmacy. This urges for initiatives on the patientlevel, but also on a broader, institutional level. The GheOP 3 S-tool could be part of such an evaluation process in which it could be the starting point for multidisciplinary interventions, initiated by the pharmacist. Such a process aims to improve the quality of prescribing for nursing home residents with polypharmacy.
